Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

FY2019-2023 figures are as at 31/05/2019

All figures shown are on an Adjusted basis unless stated. 

Please select...
£m (unless stated) 2019 2020 2021 2022 2023 2019-2023 n=
Turnover 31,784 34,612 36,095 37,582 38,975 10
Cost of sales (9,476) (10,288) (10,634) (10,960) (11,291) 10
Selling, general and administration (9,936) (10,743) (10,970) (11,241) (11,548) 10
Research and Development (4,260) (4,618) (4,802) (4,973) (5,134) 10
Royalty income 300 284 277 277 276 10
Operating profit 8,412 9,247 9,967 10,684 11,278 10
Net finance costs (919) (919) (873) (842) (812) 10
Associates 51 21 21 22 22 10
Profit before tax 7,544 8,348 9,116 9,864 10,488 10
Taxation (1,436) (1,594) (1,742) (1,885) (2,004) 10
Profit after tax  6,108 6,755 7,374 7,979 8,484 10
Minority interests* (617) (1,118) (1,209) (1,298) (1,355) 10
Profit attributable to shareholders 5,491 5,636 6,165 6,681 7,129 10
WANS (m) 4,939 4,956 4,973 4,987 5,001 10
Earnings per share (p) 111.2 113.7 124.0 134.0 142.6 10
Dividend per share (p) 80.2 80.2 80.3 80.9 81.9 10
Free Cash Flow 3,052 4,035 4,612 5,285 5,805 7
Net Debt (25,638) (24,275) (23,437) (21,940) (20,008) 9

*All of the contributing firms have reflected the Consumer Healthcare JV with Pfizer

The firms included are: Bank of America Merrill Lynch, Barclays, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, Morgan Stanley, UBS, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Anoro 523 565 608 640 664 10
Arnuity 45 50 54 58 60 10
Incruse 340 390 430 461 488 10
Relvar/Breo 1,034 1,037 1,054 1,067 1,077 10
Trelegy 437 672 918 1,094 1,241 10
Ellipta portfolio 2,379 2,714 3,064 3,320 3,530 10
Nucala 707 818 908 982 1,037 10
Total Respiratory 3,086 3,531 3,972 4,302 4,566 10
             
Tivicay 1,671 1,684 1,680 1,672 1,660 9
Triumeq 2,587 2,522 2,464 2,418 2,375 9
Juluca 332 423 497 558 609 8
Dovato 63 224 401 582 698 8
Dolutegravir based regimens 4,642 4,842 5,019 5,192 5,307 10
Cabotegravir +/- rilpivirine - 51 152 241 338 8
fostemsavir - 45 121 171 221 9
Epzicom/Kivexa 76 58 49 41 35 10
HIV 4,877 5,127 5,415 5,673 5,895 10
             
Benylsta 552 617 676 724 735 10
             
Zejula 256 385 523 662 801 10
             
Advair (US) 469 253 196 172 153 9
Seretide (ex US) 1,174 1,043 940 850 780 9
Seretide/Advair 1,643 1,296 1,135 1,022 933 10
Flixotide/Flovent 556 522 489 460 433 10
Ventolin 783 755 738 723 707 10
Avamys/Veramyst 322 333 342 346 315 10
Established Respiratory 3,561 3,153 2,940 2,778 2,605 10
Other Established Pharmaceuticals 4,719 4,498 4,277 4,093 3,909 10
Established Pharmaceuticals 8,280 7,651 7,218 6,872 6,514 10
             
belantamab mafodotin (GSK'916 BCMA) - 56 158 251 366 10
dostarlimab - 13 54 83 117 6
daprodustat - 2 36 87 154 9
             
Pharmaceuticals 17,053 17,379 18,077 18,782 19,494 10


The firms included are: Bank of America Merrill Lynch, Barclays, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, Morgan Stanley, UBS, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Bexsero 639 683 722 755 784 10
Menveo 244 257 270 284 296 10
Fluarix/Flulaval 545 563 580 598 615 10
Shingrix 1,403 1,785 2,074 2,352 2,535 10
Boostrix 544 556 570 582 595 10
Cervarix 114 120 126 131 134 10
Hepatitis 837 865 889 912 930 10
Infanrix, Pediarix 664 660 665 672 679 10
Rotarix 534 551 564 577 591 10
Synflorix 432 434 437 441 442 10
Vaccines 6,610 7,143 7,594 8,039 8,374 10


The firms included are: Bank of America Merrill Lynch, Barclays, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, Morgan Stanley, UBS, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Wellness (incl. Pfizer OTC) 4,342 6,749 6,971 7,188 7,413 9
Oral health 2,566 2,657 2,755 2,856 2,961 9
Nutrition 640 98 101 104 107 9
Skin Health 574 584 598 612 627 9
Consumer Health* 8,121 10,089 10,425 10,760 11,107 10

*All of the contributing firms have reflected the Consumer Healthcare JV with Pfizer

The firms included are: Bank of America Merrill Lynch, Barclays, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, Morgan Stanley, UBS, Wolfe Research

Back to top